Daily field note · updated 27 July 2026

Today’s EGX
research insights.

The evidence-led watchlist, the setups that failed the test, and the exact levels that would confirm or invalidate each idea. Updated after every daily automation run.

01 Fresh material disclosures
02 RV20 abnormal volume
03 Repeat-buyer clusters
04 Anti-chasing penalties

Latest run

No qualified early opportunity today.

PHAR is the only new catalyst-plus-tape overlap: EIPICO 3 was formally opened and the stock reached RV20 7.02× while still up less than 8% today. The plant is economically large, but its licence, first product and Q1 2026 operating start were already public in December 2025; today’s filing adds no order value, ramp schedule or earnings bridge. It scores 5, below the playbook’s 6-point gate.

Last updated 27 July 2026 · 10:46:43 AM Cairo Early-session snapshot · quotes delayed 15 minutes

Important

I am not telling you to invest. I am just sharing research insights.

These are watch conditions, not predictions. Prices can gap, filings can change, and liquidity can disappear. Verify every source before acting.

Thndr stocks scanned: 224
EGX lines cross-checked: 293
Post-cutoff EGX notices: 82
Qualified setups: 0

Research delta

PHAR confirms demand—but not a newly quantified catalyst.

All quote-layer figures below were captured at 10:46:43 AM Cairo from a 15-minute-delayed feed. Intraday RV20 is provisional.

Since the prior run

PHAR · developing watch · 5/13 · medium confidence

Catalyst: The opening took place 26 July 2026; Mubasher published the event at 5:54 PM Cairo and the EGX issuer statement followed 27 July at 8:44 AM Cairo. EIPICO 3 exceeds US$100m, spans 10,500 m² and can manufacture biologicals and biosimilars from cell line to finished product. Expected future commercial milestone: not disclosed. The company had already announced the operating licence, ADALIMAB launch, UPA supply award and Q1 2026 operating start on 11 December 2025.
Price and volume: EGP 96.00 at 10:46:43 AM Cairo, +6.55% since the pre-catalyst close. The 26 July session had fallen 1.53% to EGP 90.10 before the opening news. Performance: 1W +5.63%, 1M +8.50%, 3M +11.00%. Volume was 1,262,873 versus a preceding-20-session median of 179,957: RV20 7.02×. The quote sat 75.6% up the EGP 90.10–97.90 range. Normal 30-day traded value is EGP 13.92m.
Accumulation path: The first recent anomaly was 15 July: RV20 7.59×, +2.13%, 66.2% close location. Abnormal volume repeated on 16, 19, 20, 22 and 26 July before today’s catalyst-day demand. That makes the stage developing rather than truly first-day early; no named buyer or ownership crossing explains the sequence.
Materiality and ownership: At today’s quote, 168.756m shares imply a EGP 16.20bn market cap. Using the CBE’s latest available 20 July midpoint of EGP 51.0794/US$, the project is roughly EGP 5.108bn: 31.5% of market cap and 54.1% of FY2025 revenue. This is invested project cost—not new revenue or profit. Exchange float is 31.64%, leaving 68.36% strategically concentrated.
Operating trend: Q1 consolidated sales rose about 10.5% to EGP 2.53bn, but operating profit was nearly flat at EGP 698.2m versus EGP 699.5m and net profit fell 10.5% to EGP 284.4m. TTM revenue / operating profit / net profit are EGP 9.674bn / 2.340bn / 1.407bn. EGP 495.5m of TTM equity-investment earnings sits below operations; meanwhile cash is EGP 362.8m, debt EGP 9.47bn and TTM operating cash flow is negative EGP 86.8m. The factory’s contribution is not yet separately visible.
Score and trade map: +1 fresh but mostly confirmatory disclosure, +2 economic importance, +2 RV20/price confirmation, +0 named buyer and +0 dated future catalyst = 5/13. Confirm only on a full-session close above EGP 97.90 with RV20 ≥3×, close location ≥75% and traded value ≥EGP 13.92m. Invalidate on a daily close below EGP 90.10. Risk-based initial targets: EGP 105.70 / 113.50. Time-stop: 2 August close if no follow-through or quantified commercial update.

EGX issuer statement · 27 July, 8:44 AM Cairo Factory-opening report · 26 July EIPICO licence, launch and UPA award · 11 December 2025 Egyptian Drug Authority inspection · primary PDF CBE exchange-rate reference

Ranked watches

Closest setups, with exact gates

1 · PHAR · 5/13: New / developing / medium confidence. EGP 96.00, +6.55%; 1W +5.63%, 1M +8.50%, 3M +11.00%; RV20 7.02×, 75.6% close location and EGP 13.92m normal value. Exact gate: close above 97.90 on RV20 ≥3× and top-quartile strength; invalidate 90.10; targets 105.70 / 113.50; time-stop 2 August.
2 · BONY · 5/13: Unchanged carry / medium–low confidence. EGP 5.11; 1W +6.68%, 1M +3.23%, 3M +15.61%; RV20 only 0.21×. The 10% bonus remains value-neutral; entitlement ends 5 August and adjusted listing is 6 August. Confirm above 5.14 only with RV20 ≥3× and a top-quartile close; invalidate 4.79; targets 5.48 / 5.95; time-stop 5 August.
3 · ARVA · 4/13: Fading carry / low–medium confidence. EGP 12.30, −1.36%; 1W +13.68%, 1M +10.02%, 3M +64.00%; RV20 has fallen to 0.87×. Today’s AGM outcome was not published by the cutoff. Require a clean outcome and close above 12.60 with RV20 ≥3×; invalidate 11.65; targets 13.23 / 13.85; time-stop 30 July.

PHAR delayed quote and chart BONY quote and announcements ARVA quote and filings

Rejection log

Tempting movers that failed

ASPI: The second-stage rights issue was covered 79.8×, but it creates 1.9bn shares and lifts total shares from 2.0bn to 3.9bn—about 95% dilution. After 26 July’s +8.49% / RV20 3.53× burst, today is −1.77%, RV20 0.39× and only 23.1% up the range. Strong subscription demand does not erase dilution or the late entry.
BIOC: EGP 134.01, +12.61%, RV20 5.97× and 76.6% close location look powerful, but the stock is already +88.69% in one month, free float is only 2.91% and normal value only EGP 2.77m. The playbook’s denial, late-move and exit-liquidity penalties reject it.
DGTZ / ISMA / AJWA: DGTZ has RV20 2.41× with no fresh material filing. ISMA’s first anomaly was yesterday at RV20 6.27×, but it is already +83.64% in three months and has no new catalyst. AJWA reached RV20 2.17× after yesterday’s 13.89× spike, yet the AGM agenda remains economically unquantified. Tape alone is not evidence.
PHDC / AIH / RAYA: PHDC insiders bought a gross 1.36m shares—only 0.048% of shares—and today’s RV20 is 0.09×; the FRA purpose amendment states no effect on obligations or equity. AIH’s related-group 500k buy is 0.032% with RV20 0.04×. RAYA transferred 3.5m incentive shares for EGP 26.565m, just 0.082% of shares, while a related group separately sold 2m shares; RV20 is 0.08×.
AMES / SVCE: AMES is +162.85% in one month and +293.38% in three months, so today’s near-limit move is irreparably late. SVCE’s Q1 results are not accompanied by confirmation: RV20 is 0.04× and the quote sits 25.8% up the range.
CFGH: RV20 is 1.88× and normal 30-day traded value is only about EGP 5,040. Even a correct catalyst would not provide an acceptable entry-and-exit route.

ASPI subscription result EGX insider-dealing report · 26 July session Today’s EGX announcement tape

Ownership cross-check

No new post-cutoff 5% crossing, named repeat buyer or cross-company buyer cluster qualified. PHAR disclosed no buyer name, shares, ownership before/after, transaction price, transaction date or broker. The 26 July insider report identifies roles rather than names and omits prices, before/after stakes and brokers; PHDC’s gross 1.36m-share buying and AIH’s 500k-share purchase are immaterial relative to shares outstanding. RAYA’s employee transfer was 3.5m shares for EGP 26.565m—about EGP 7.59 per share—but it is an incentive-plan transfer, not evidence of a major buyer.

Recent monitor history

What stayed, faded, or was rejected.

This rolling history keeps the last five completed reports visible. Leaving today’s shortlist means “no material change,” not that the earlier signal was erased.

ACGC trail

Exceptional volume, then a reporting-risk filing.

22 July · −1/13: ACGC closed at EGP 10.89, +7.23%, on RV20 7.46× with a 91.2% close location. The after-close EGX decision imposed a EGP 40,000 penalty for late financial reporting and granted another 15 days to submit the consolidated statements for the period ended 31 March 2026. The fine was immaterial; the missing information was not.
27 July check: EGP 10.60 at 11:27:16 AM Cairo, −1.30% today and −2.66% from the 22 July signal close. Performance was 1W +7.61%, 1M +10.30% and 3M +27.25%. Volume was 568,999 versus a 1,792,903 median: RV20 0.32×, with a 17.2% close location. Normal 30-day traded value is EGP 18.26m and free float 78.79%. No newer ACGC disclosure appeared after the 22 July committee decision.
Status: Still rejected / low confidence. Reconsider only after the overdue consolidated statements are filed, a positive economically material catalyst or named buyer appears, and price closes above EGP 10.90 with RV20 ≥3× and top-quartile strength. The old EGP 10.15 invalidation remains the downside reference; historical targets EGP 11.45 / 12.00 are inactive while the rejection stands.

ACGC announcement history 22 July listing-committee decision summary

Rolling five-report ledger

The shortlist in context

27 July: No qualified opportunity. PHAR became the new leader at 5/13; BONY remained 5/13; ARVA faded but remained a 4/13 carry. ACGC’s volume confirmation disappeared and no new filing changed its rejection.
26 July: No qualified opportunity. ARVA led at 4/13 on repeated volume but an incomplete, three-week-old order disclosure and governance risk. BONY remained 5/13; MICH’s fresh results scored 2/13.
25 July: No qualified opportunity during the weekend carry. BONY held at 5/13, ATQA at 2/13 and ACGC at −1/13; no new market session supplied confirmation.
23 July: No qualified opportunity. BONY remained the closest watch at 5/13. ATQA’s RV20 3.60× was tape-only, while ACGC’s RV20 7.46× was rejected because the catalyst was negative and reporting quality deteriorated.
22 July: No qualified opportunity. BONY and COMI scored 5/13, OLFI 4/13 and ADPC 1/13. No named major buyer or repeat-buyer cluster qualified.